Trial Profile
A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 Mg and Celecoxib 200 Mg in Patients With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Rofecoxib (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Oct 2005 New trial record.